Skip to contentA
Amphastar Pharmaceuticals, Inc.
A
AMPHAmphastar Pharmaceuticals, Inc. Q1 2019 · 10-Q
Revenue$79.79M$79.79M+36.6% vs Q1 2018 Net Income$868.00K$868.00KN/M vs Q1 2018 EPS Diluted$0.02$0.02N/M vs Q1 2018 Gross Profit$30,903,000+82.1% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Amphastar Pharmaceuticals, Inc. · CIK 1297184 · Engraved from SEC EDGAR
Operating Cash Flow-$3,610,000N/M Free Cash Flowderived-$18,354,000N/M Margins · derivedGross margin38.7%+9.7 pt vs Q1 2018
Operating margin-4.0%+12.8 pt vs Q1 2018
Net margin1.1%+13.3 pt vs Q1 2018
ended Mar 31, 2019 · filed May 10, 2019 · 40 d after period end